The authors describe an industrialized process for the manufacture of iPSC-derived human cardiomyocytes. This article is part of a special issue on Bioprocessing and Sterile Manufacturing.
Blake Anson
Advertisement
Blake Anson is iCell Cardiomyocyte product managerat Cellular Dynamics International, 525 Science Drive, Madison, WI 53711.
Articles by Blake Anson
Advertisement
Latest Updated Articles
Industrialized Production of Human iPSC-Derived Cardiomyocytes for Use in Drug Discovery and Toxicity TestingPublished: March 1st 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Standardizing Operations to Meet Global Sustainability and Resilience Goals
2
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
3
Takeda’s Sriman Banerjee Discusses Smart Packaging at CPHI Frankfurt 2025
4
PharmTech Weekly News Roundup — Week of October 27, 2025
5
